News Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal Cancer drug developer Veraxa Biotech has reached a deal to merge with a SPAC in a deal that will give it a Nasdaq listing and a $1.6bn-plus valuation.
News Ouro makes debut with $120m for autoimmune disease TCEs Ouro launches today with $120m in funding and a plan to develop bispecific antibody-based T cell engagers for autoimmune diseases.
Oncology ASCO 2024 - Matteo Levisetti ASCO 2024 marked the 10th anniversary of checkpoint inhibitors, which powerfully changed the nature of cancer immunotherapy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face